On the 25th, the State Food and Drug Administration approved the registration application of azvudine tablets of Henan Zhenzhen Biotechnology Co., Ltd. to increase the indications for the treatment of novel coronavirus pneumonia in accordance with the special drug approval procedures. The drug is an oral small molecule novel coronavirus pneumonia treatment drug independently developed in China. On July 20, 2021, the State Food and drug administration has conditionally approved the drug in combination with other reverse transcriptase inhibitors to treat adult HIV-1 infected patients with high viral load. This is a conditional approval of new indications for the treatment of adult patients with common novel coronavirus pneumonia. Patients should take medicine in strict accordance with the instructions under the guidance of doctors. The State Food and drug administration requires the listing permit holder to continue to carry out relevant research work, complete the conditional requirements within a time limit, and submit the follow-up research results in time. (outlook new era)